Janus Henderson Group PLC Cardiff Oncology, Inc. Transaction History

Janus Henderson Group PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.17 - $2.61 $2.04 Million - $4.55 Million	-1,742,123 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.11 - $7.25 $3.76 Million - $12.9 Million	-1,780,889 Reduced 50.55%	1,742,123 $4.32 Million
Q4 2021 Feb 14, 2022	SELL	$5.18 - $7.24 $53,711 - $75,071	-10,369 Reduced 0.29%	3,523,012 $21.2 Million
Q3 2021 Nov 16, 2021	BUY	$5.01 - $7.58 $1.91 Million - $2.9 Million	382,214 Added 12.13%	3,533,381 $23.5 Million
Q2 2021 Aug 16, 2021	BUY	$6.65 - $10.04 $1.42 Million - $2.15 Million	213,985 Added 7.29%	3,151,167 $21 Million
Q1 2021 May 17, 2021	BUY	$9.1 - $19.57 $7.28 Million - $15.6 Million	799,511 Added 37.4%	2,937,182 $27.2 Million
Q4 2020 Feb 16, 2021	BUY	$12.02 - $24.71 $13.5 Million - $27.8 Million	1,124,853 Added 111.06%	2,137,671 $38.4 Million
Q3 2020 Nov 16, 2020	BUY	$4.25 - $14.19 $4.3 Million - $14.4 Million	1,012,818 New	1,012,818 $14.4 Million

125

25.3M

866K

203K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $163M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.